Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
Xiaosong Shang1, Xinyu Na1, Lei Wang1
1Department of Urology, Zhenhai People's Hospital, Ningbo, Zhejiang, China.
Abstract:
Targeting the phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signalling pathway is a promising strategy for the treatment of various cancers, including bladder cancer (BC). PF-04691502 is a relatively novel dual PI3K/mTOR inhibitor that exerts inhibitory effects against various cancer cells. However, the effects of PF-04691502 in BC cells have not been clarified thus far. This study aimed to evaluate the antitumour effects of PF-04691502 and the mechanisms underlying these antitumour effects in BC cells. The effects of PF-04691502 on the viabilities of BC cells were examined using the cell counting kit 8 (CCK-8) assay. Cell migration and invasion were measured using the wound healing assay and transwell assay, respectively. Cellular apoptosis was determined using flow cytometry. The change in the cellular protein levels was measured using western blotting. siRNA was used to study the role of PTEN in the antitumour effects of PF-04691502. PF-04691502 inhibited the proliferation, migration, and invasion of BC cells. Additionally, PF-04691502 induced apoptosis of BC cells via the intrinsic pathway. PF-04691502 inhibited the expression of Mcl-1 and the PI3K/Akt/mTOR pathway in BC cells. In addition, PF-04691502 increased the apoptosis induced by various chemotherapeutic agents in BC cells. Taken together, PF-04691502 could be used alone or in combination with other chemotherapeutic agents in the treatment of BC.
Insights
PF-04691502, a dual PI3K/mTOR inhibitor, effectively suppresses bladder cancer (BC) cell proliferation, migration, and invasion. This agent also promotes apoptosis and enhances chemotherapy efficacy, suggesting its potential as a BC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a key target for cancer therapy.
- Bladder cancer (BC) remains a significant health concern, necessitating novel therapeutic strategies.
- PF-04691502 is a novel dual PI3K/mTOR inhibitor with demonstrated anti-cancer effects in various cell types.
Purpose of the Study:
- To investigate the anti-tumor effects of PF-04691502 in bladder cancer (BC) cells.
- To elucidate the underlying mechanisms of PF-04691502's anti-tumor activity in BC.
- To assess the potential of PF-04691502 as a therapeutic agent for BC.
Main Methods:
- Cell viability was assessed using the cell counting kit 8 (CCK-8) assay.
- Cell migration and invasion were evaluated via wound healing and transwell assays.
- Apoptosis, protein expression (including Mcl-1 and PI3K/Akt/mTOR pathway components), and PTEN's role were analyzed using flow cytometry, western blotting, and siRNA.
Main Results:
- PF-04691502 significantly inhibited BC cell proliferation, migration, and invasion.
- The compound induced apoptosis in BC cells through the intrinsic pathway.
- PF-04691502 downregulated Mcl-1 expression and suppressed the PI3K/Akt/mTOR pathway.
- PF-04691502 potentiated the apoptotic effects of chemotherapeutic agents in BC cells.
Conclusions:
- PF-04691502 exhibits potent anti-tumor activity against bladder cancer cells.
- The drug functions by inhibiting proliferation, invasion, and the PI3K/Akt/mTOR pathway, while inducing apoptosis.
- PF-04691502 holds promise as a monotherapy or combination therapy for bladder cancer treatment.
